B Braun's nerve mapping "pen":
This article was originally published in Clinica
Executive Summary
B Braun has received US FDA 510(k) clearance for its Stimuplex Pen for mapping the location of nerves under the skin, prior to administering anaesthesia. It is thought that the device could improve the efficiency of local anaesthetic administration, making it a more attractive option, particularly in rapid turnover environments. The Stimuplex Pen focuses a very small current from a Stimuplex HNS 11 or HNS 12 nerve stimulator in order to identify nerves up to 3cm beneath the skin.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.